Recombinant Virus Encoding One Or More Heterologous Proteins Or Fragments Thereof Patents (Class 424/199.1)
  • Patent number: 10729757
    Abstract: Novel nucleic acid molecules encoding a pre-fusion RSV F protein or immunologically active part thereof are described, and the pre-fusion RSV F protein contains the amino acid sequence of SEQ ID NO: 1 or 2. Use of the nucleic acid molecules, or vectors containing the nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV) is also described.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: August 4, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Janneke M. Verhagen
  • Patent number: 10702599
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: July 7, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Patent number: 10702591
    Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-,8-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: July 7, 2020
    Assignee: Panacea Pharmaceuticals, Inc.
    Inventors: Biswajit Biswas, Carl R. Merril, Hossein Ghanbari
  • Patent number: 10653769
    Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: May 19, 2020
    Assignee: MEDIGEN, INC.
    Inventors: Peter Pushko, Igor Lukashevich
  • Patent number: 10590435
    Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: March 17, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 10576143
    Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: March 3, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Riccardo Cortese, Antonella Folgori, Alfredo Nicosia
  • Patent number: 10548972
    Abstract: The present invention provides an attenuated strain of porcine pseudorabies virus (PRV), in which said attenuated strain of PRV is a variant strain of PRV with inactivation of gI/gE/11K/28K proteins. In addition, the present invention also provides a vaccine composition comprising the attenuated strain of PRV as an antigen, a preparation method and use thereof. Proved by immunogenicity and pathogenicity testing of the live vaccine, said live PRV vaccine can provide a good protection for pigs with no clinical signs observed, indicating excellent immune protection.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: February 4, 2020
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Xuke Zhang, Jinzhong Sun, Feifei Tan
  • Patent number: 10543269
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: January 28, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Patent number: 10532099
    Abstract: Disclosed are CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV. Immunization with the disclosed CMV vectors allow selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: January 14, 2020
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli, Jay Nelson, Jonah Sacha, Meaghan Hancock
  • Patent number: 10525127
    Abstract: The present invention Provides composition and method for stimulating immune responses against antigens without using conventional adjuvants (such as aluminum salt adjuvants, oil-in-water emulsion adjuvants, toll-like receptor agonist adjuvants, and the like). The composition contains p14.7 protein and an antigen to which the stimulated illumine responses are desired. The p14.7 protein functions as an adjuvant so that the immune responses to the antigen stimulated by the composition comprising p14.7 protein and the antigen are greater than the immune responses stimulated by the antigen alone. The current invention also provides a method for producing thermostable vaccines and a simple strategy for avoiding vaccine cold-chain maintenance by lyophilization.
    Type: Grant
    Filed: March 31, 2018
    Date of Patent: January 7, 2020
    Assignee: Femtomab
    Inventor: Wenyun Zhou
  • Patent number: 10517943
    Abstract: The present invention relates to liquid formulations of poxvirus, in particular vaccinia virus, stable during storage. Such stable liquid formulations comprise a) a poxvirus, preferably a vaccinia virus, b) a pharmaceutically acceptable buffer, c) a monovalent salt, d) a pharmaceutically acceptable disaccharide or sugar alcohol, and e) a pharmaceutically acceptable chelating agent, wherein the pH of the formulation is comprised between 6.5 and 8.5.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 31, 2019
    Assignee: Transgene S.A.
    Inventor: Mélina Chasle
  • Patent number: 10493144
    Abstract: The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: December 3, 2019
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Justin Widener, Leszlie Woodyard, Leonardo Siger, Douglas Brough, Damodar Ettyreddy, Jason Gall, Duncan McVey, Tom Burrage, Lauri Motes-Kreimeyer, Marc Fiorucci
  • Patent number: 10480013
    Abstract: The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS1 protein, wherein the vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing the influenza virus vector, its use for the treatment of cancer patients and methods for producing the influenza virus vaccine.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: November 19, 2019
    Assignee: BLUE SKY VACCINES GMBH
    Inventors: Thomas Muster, Markus Wolschek
  • Patent number: 10465170
    Abstract: Described herein are mutant pneumoviruses comprising a nucleotide sequence which encodes a mutated zinc binding motif in an M2-1 protein of the pneumovirus, wherein the zinc binding motif is mutated relative to wild-type pneumovirus. The mutant pneumoviruses described herein grow to high titer in cell culture, are genetically stable, are attenuated in vitro and in vivo, and are highly immunogenic. Also described herein are vaccines and vaccine compositions comprising the live attenuated mutant pneumoviruses. Vaccine compositions can further comprise a pharmaceutically acceptable carrier, vehicle, excipient, and/or adjuvant. Methods for inducing a protective immune response in a subject against a pneumovirus infection are also described and disclosed.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: November 5, 2019
    Assignees: Ohio State Innovation Foundation, Research Institute at Nationwide Children's Hospital
    Inventors: Mark E. Peeples, Jianrong Li, Hui Cai, Rongzhang Wang
  • Patent number: 10441643
    Abstract: This document provides methods and materials for treating cancer. For example, methods and materials for treating cancer using combinations of antigens are provided. For example, VSV vectors designed to express a GNAQ antigen, a TYRP1 antigen, and an N-RAS antigen can be used to reduce the number of cancer cells (e.g., uveal melanoma cells) within a mammal (e.g., a human). In some cases, VSV vectors designed to express a BRAF antigen, a TOPO-11a antigen, and a YB-I antigen can be used to reduce the number of cancer cells (e.g., skin melanoma cells) within a mammal (e.g., a human). The composition can comprise less than 50 separate nucleic acid molecules.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: October 15, 2019
    Assignees: Mayo Foundation for Medical Education and Research, University of Leeds
    Inventors: Jose S. Pulido, Richard G. Vile, Timothy J. Kottke, Jill M. Thompson, Rosa Maria Diaz, Christine Marie Pulido, Alan A. Melcher, Peter Selby
  • Patent number: 10434166
    Abstract: Disclosed are compositions and methods comprising a vector and a reverse genetics competent unit. The vector may comprise baculovirus expression vectors, bacmids, vaccinia virus and synthetic vectors and the reverse genetics competent unit may comprise pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector. In certain embodiments, the reverse genetics competent unit comprises pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector for influenza virus.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: October 8, 2019
    Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Daniel R. Perez, Hongjun Chen
  • Patent number: 10428118
    Abstract: Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: October 1, 2019
    Assignee: Oregon Health & Science University
    Inventors: Klaus Frueh, Scott G. Hansen, Jay Nelson, Louis Picker, Patrizia Caposio
  • Patent number: 10398769
    Abstract: Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA Influenza A of serotype H7N9 alone and in combination with HA hemagglutinin and/or influenza B hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza A serotypes and/or influenza B serotypes, or combinations thereof, using the vaccines that are provided.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: September 3, 2019
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David B. Weiner, Jian Yan
  • Patent number: 10383934
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: August 20, 2019
    Assignee: Zoetis Services LLC
    Inventors: Jay Gregory Calvert, Robert G. Ankenbauer, Jacqueline Gayle Marx, Douglas S. Pearce, Marcia L. Keith
  • Patent number: 10370679
    Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: August 6, 2019
    Assignees: ARIZONA BOARD OF REGENTS, a body corporate of the State of Arizona acting for and on behalf of Ariz, CONSEJO SUPERIOR DE INVESTGACIONES CIENTRIFICAS, IPPOX FOUNDATION
    Inventors: Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mariano Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias El Haddad, James Tartaglia
  • Patent number: 10301600
    Abstract: The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: May 28, 2019
    Assignee: BioVex Limited
    Inventor: Robert S. Coffin
  • Patent number: 10300132
    Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: May 28, 2019
    Assignee: Altimmune UK Limited
    Inventors: Bertrand Victor Gilbert Georges, Carlton Bradley Brown
  • Patent number: 10293040
    Abstract: The present invention is directed to pharmaceutical compositions and methods of inhibiting or blocking one or more virulence antigenic factors of Bacillus anthracis. Specifically, it involves the administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of an antigenic factor of Bacillus anthracis attached through a linker to the aminoterminal end of the CD40 ligand. This fusion protein has the ability to generate antibodies which prevents Bacillus anthracis infection in an individual.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 21, 2019
    Assignee: MICROVAX, LLC
    Inventor: Albert B. Deisseroth
  • Patent number: 10279029
    Abstract: Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 7, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria A. Croyle, Stephen Clay Schafer
  • Patent number: 10273285
    Abstract: The present disclosure relates to fusion proteins that are highly useful for the generation of virus-like particles for the display of membrane spanning proteins. Related embodiments, methods and uses are disclosed.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: April 30, 2019
    Assignee: MORPHOSYS AG
    Inventors: Sebastian Jaeger, Daniela Daubert, Kathrin Goetz
  • Patent number: 10265393
    Abstract: Disclosed are yeast-based immunotherapeutic compositions, human immunodeficiency virus (HIV) antigens, and fusion proteins for the treatment and/or prevention of HIV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HIV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HIV and/or symptoms thereof.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: April 23, 2019
    Assignee: GlobeImmune, Inc.
    Inventors: Thomas H. King, David Apelian
  • Patent number: 10251951
    Abstract: The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: April 9, 2019
    Assignee: CEVA SANTA ANIMALE
    Inventors: Ayumi Fujisawa, Mayumi Kubomura, Sakiko Saeki, Shuji Saito
  • Patent number: 10201605
    Abstract: The present invention provides an attenuated strain of porcine pseudorabies virus (PRV), in which said attenuated strain of PRV is a variant strain of PRV with inactivation of gI/gE/11K/28K proteins. In addition, the present invention also provides a vaccine composition comprising the attenuated strain of PRV as an antigen, a preparation method and use thereof. Proved by immunogenicity and pathogenicity testing of the live vaccine, said live PRV vaccine can provide a good protection for pigs with no clinical signs observed, indicating excellent immune protection.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: February 12, 2019
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Xuke Zhang, Jinzhong Sun, Feifei Tan
  • Patent number: 10188721
    Abstract: The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: January 29, 2019
    Assignee: Merial, Inc.
    Inventors: Justin Widener, Leszlie Woodyard, Leonardo Siger, Douglas Brough, Damodar Ettyreddy, Jason Gall, Duncan McVey, Tom Burrage, Lauri Motes-Kreimeyer, Marc Fiorucci
  • Patent number: 10188720
    Abstract: The present invention relates recombinant viruses and the uses thereof. More particularly, the invention relates to novel recombinant Marek's disease viruses encoding polypeptide(s) of interest, and their use to express or deliver such polypeptides to animals, particularly poultry. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: January 29, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventors: Motoyuki Esaki, Shuji Saitoh, Takanori Sato
  • Patent number: 10155930
    Abstract: The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or oncogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: December 18, 2018
    Inventor: Per Sonne Holm
  • Patent number: 10130702
    Abstract: The present disclosurerelates to a vaccine composition, wherein the vaccine composition comprises an immune amount of fowl adenovirus Fiber-2 protein or an immune amount of a live vector recombined with gene of the fowl adenovirus Fiber-2 protein, and a pharmaceutically acceptable carrier. The vaccine composition can provide effective immune protection against different serotypes of adenoviruses and provide a protection rate of 100% at low levels of immunogenic components, showing good immunological efficacy.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: November 20, 2018
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Wenqiang Pang, Jinzhong Sun, Xuke Zhang
  • Patent number: 10125174
    Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: November 13, 2018
    Assignee: GenVec, Inc.
    Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski
  • Patent number: 10124057
    Abstract: The present invention provides a method for enabling ducklings to quickly produce anti-avian influenza antibodies and maintain antibody titer, including: step 1) the first immunization is performed on ducklings at the age of 5 to 15 days: each duckling is inoculated with an avian influenza inactivated antigen in an abdomen, and simultaneously intramuscularly or subcutaneously immunized with an avian influenza inactivated oil-emulsion vaccine. In the method, through the double effects of intraperitoneal inoculation with the inactivated antigen and intramuscular or subcutaneous injection with the inactivated oil-emulsion vaccine on the ducklings, the ducklings can quickly produce an immune response so as to quickly produce the anti-avian influenza antibodies; and the immune dead time of the ducklings immunized with the avian influenza inactivated vaccine can be effectively reduced by more than 7 days.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: November 13, 2018
    Inventors: Ruiai Chen, Aiguo Zhang, Yufu Liu, Jiahua Xu, Shuqiong Zhang, Wenke Huang, Daxing Wu, Shichang Liao
  • Patent number: 10111946
    Abstract: The invention is drawn to compositions and methods for the induction of an immune response, in particular a strong CD8 T cell response, to a specific antigenic determinant without raising a significant antibody response to the antigenic determinant after a first, priming immunization. The method comprises administering to the host a recombinant poxviral vector comprising a transcriptional control element comprising an early and/or late element linked to a nucleotide sequence encoding the antigenic determinant. The recombinant poxviral vector comprises a transcriptional control element comprising an early and/or late element linked to a nucleotide sequence encoding the antigenic determinant. The late element may be stronger than the cowpox ATI promoter in HeLa cells.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: October 30, 2018
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Robin Steigerwald, Kay Brinkmann, Ulrike Dirmeier, Paul Chaplin
  • Patent number: 10076562
    Abstract: Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 18, 2018
    Assignees: The Board of Regents of the University of Texas System, Norwell, Inc.
    Inventors: Ashok K. Chopra, Vladimir L. Motin, Eric Rothe
  • Patent number: 10064934
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: September 4, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Patent number: 10067142
    Abstract: An object of the present invention is to provide a novel method of diagnosing and/or treating a mood disorder, the method being superior to the conventional technologies. The present invention attains the object by providing a method of diagnosing and/or treating a mood disorder by use of an anti-SITH-1 antibody level and an anti-HHV-6 antibody level each serving as an index.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: September 4, 2018
    Assignees: JAPAN TOBACCO INC., VIRUS IKAGAKU KENKYUSHO INC.
    Inventors: Kazuhiro Kondo, Nobuyuki Kobayashi, Naomi Oka
  • Patent number: 10053496
    Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: August 21, 2018
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali
  • Patent number: 10039796
    Abstract: The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 has fusogenic activity, and comprises a modified/mutated ICP10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: August 7, 2018
    Assignee: The University of Houston System
    Inventors: Xiaoliu Zhang, Xinping Fu
  • Patent number: 10018618
    Abstract: An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an ?-helical moiety, or one or more proline residues.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: July 10, 2018
    Assignee: Peptide BioSciences, Inc.
    Inventor: Elliot Altman
  • Patent number: 10010600
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: July 3, 2018
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
  • Patent number: 9944966
    Abstract: The invention relates to a method for production of single-stranded macronucleotides by amplifying and ligating an extended monomeric single-stranded target nucleic acid sequence (targetss) into a repetitive cluster of double-stranded target nucleic acid sequences (targetds), and subsequently cloning the construct into a vector (aptagene vector). The aptagene vector is transformed into host cells for replication of the aptagene and isolated in order to optain single-stranded target sequences (targetss). The invention also relates to single-stranded nucleic acids, produced by a method of the invention.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: April 17, 2018
    Assignee: Technische Universität Kaiserslautern
    Inventors: Ralf Stadtmüller, Nils Tippkötter, Roland Ulber
  • Patent number: 9931395
    Abstract: In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM/gN or gO.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: April 3, 2018
    Assignee: CITY OF HOPE
    Inventors: Don J. Diamond, Felix Wussow
  • Patent number: 9913892
    Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: March 13, 2018
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., CORNELL RESEARCH FOUNDATION, INC., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
  • Patent number: 9884080
    Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: February 6, 2018
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Johann Foloppe
  • Patent number: 9878033
    Abstract: Certain embodiments of the present invention provide immunogenic compositions that comprise one or more peptides having an amino acid sequence selected from the group consisting of NLLTTPKFT and RMLGDVMAV and methods for administering such compositions to a mammal and thereby inducing in the mammal a CD8+ T cell-dependent protective immunity against an HSV-1 infection, an HSV-2 infection, an HSV-1 condition, an HSV-2 condition, or combinations thereof.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: January 30, 2018
    Assignee: The Regents of the University of California
    Inventors: Lbachir BenMohamed, Anthony Nesburn
  • Patent number: 9872899
    Abstract: Novel compositions useful as human rhinovirus immunogens are provided. The compositions enable a host response to sites normally not recognized by a host.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: January 23, 2018
    Assignee: Biological Mimetics, Inc.
    Inventors: Gregory J Tobin, Peter L Nara
  • Patent number: 9856469
    Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: January 2, 2018
    Assignee: The Board of Trustees of The Leland Stanford Junior University
    Inventors: Leszek Lisowski, Mark A. Kay
  • Patent number: 9833502
    Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: December 5, 2017
    Assignee: GenVec, Inc.
    Inventors: Ping Chen, Duncan McVey, Douglas Brough, Joseph Bruder